Q4 has a molecule attached
Somewhere in the next four months, the FDA is expected to decide on the first once-weekly combination of a GLP-1 and an amylin analogue. Novo Nordisk filed the CagriSema NDA on December 18, 2025 and has said a US decision is expected in Q4 2026. There is no public PDUFA date, which means, like the 503B order, this lands on an ordinary weekday with no warning.
The pipeline picture sharpened over the summer in one other way: retatrutide, the triple agonist whose trial results reset outcome expectations, now looks like a filing around year-end or early 2027, with approval a 2027 to 2028 story. So the next-molecule event your program will actually face this year is CagriSema. That makes it the perfect drill: whatever the decision says, the program that can absorb a new molecule in a week, education, intake, formulary, pricing, comms, owns every future approval too. Readiness, not prediction, is the asset. Here is the plan.
What is confirmed, what is open
| Question | What we know | Status |
|---|---|---|
| What CagriSema is | Once-weekly combination of semaglutide and the amylin analogue cagrilintide | Confirmed |
| Filing | NDA filed December 18, 2025 | Confirmed |
| Decision timing | Novo says a US decision is expected Q4 2026 | Company statement; no public PDUFA date |
| Efficacy evidence | The placebo-controlled REDEFINE-1 and REDEFINE-2 trials anchor the filing; the REDEFINE-4 head-to-head showed 23% weight loss at 84 weeks but missed its non-inferiority primary endpoint against tirzepatide 15 mg | Reported |
| Label, pricing, supply, distribution | Not announced | Open |
| Retatrutide | Filing now expected around year-end or early 2027 | Reported plans; softer than earlier signals |
The REDEFINE-4 miss matters for positioning more than for approvability: the filing rests on the placebo-controlled program. If approved, CagriSema arrives as a strong option among strong options, not a category reset, which changes the marketing register from "the new best thing" to "another well-matched tool." The wider pipeline context is in Next-Generation GLP-1s in 2026, and the outcome-expectation arc in The Thirty Percent Era.
The Real 2026 Peptide Timeline
Removal from Category 2 is the first gate, not the last. The path from April 2026 to a legally compoundable peptide runs through the PCAC meeting, an FDA determination, and 503A Bulks List inclusion.
- 1April 22, 2026Complete
Removed from Category 2
BPC-157, TB-500, KPV, MOTs-c, Semax, Epitalon, and DSIP exit the FDA's significant-safety-concerns list. Compounding still not authorized.
- 2July 9, 2026Upcoming
Public comment deadline
Final day to submit comments to docket FDA-2025-N-6895. Comments after this date are not presented to the committee.
- 3July 23-24, 2026Upcoming
PCAC meeting at White Oak
Pharmacy Compounding Advisory Committee reviews and votes on adding peptides to the 503A Bulks List. Day 1 covers BPC-157, KPV, TB-500, MOTs-c. Day 2 covers DSIP, Semax, Epitalon.
- 4Post-meetingPending FDA
FDA determination
FDA reviews the PCAC recommendations and publishes a determination, typically through a notice or proposed rule. Usually months, not days.
- 5503A Bulks ListPending FDA
Compounding becomes legal
Once a peptide is formally included, licensed 503A pharmacies may compound for individual patients with a valid prescription, subject to the rest of the framework.
Education pages: the update rhythm is the product
Patients are already asking about CagriSema, and your education pages are answering whether you maintain them or not. The standing rule until approval: watchlist language. Not approved, not available, here is what the trials showed, here is how a decision would reach our formulary. The moment that language slips into implied availability, you have a compliance problem; the moment it goes stale, you have a credibility problem with the best-informed patients in the funnel.
So put the pages on a rhythm rather than a wish: a monthly review pass with a visible updated date, and a same-day pass when news lands. Fresh, dated, plainly structured pages are also what AI assistants cite when patients ask "when will CagriSema be available," which makes maintenance an acquisition activity, not a chore. Slot the rhythm into the same operating calendar you built from the H2 metabolic calendar, with one named owner.
Intake and formulary: adding a molecule should be configuration
Here is the test that decides whether approval week is exciting or existential: can your program add a medication by changing settings, or does it require engineering? Walk the chain now, because every link has to absorb the new molecule:
- Catalog and formulary: a new product with its own strengths, titration schedule, and program pairing, created as data, not as a development ticket.
- Intake: eligibility and screening logic that branches for the new option without rebuilding the questionnaire, so the same form quietly gains one more path.
- Provider workflow: protocol and prescribing guidance loaded where clinicians review cases, with state-aware routing untouched.
- Pharmacy: routing rules that add the new product across your partners as supply actually materializes, partner by partner, not all-or-nothing.
- Billing: a price and subscription plan attached to the product, live the same day.
If any link needs a replatform, fix that this fall, while the deadline is soft. This is the drill's real payoff: the same chain absorbs retatrutide in 2027, the next oral, and everything after. It is also, plainly, how we built Turbopills: products, intake branches, and pricing are configuration, so a new molecule is an afternoon of setup and a clinical sign-off, not a quarter of engineering.
Pricing scenarios: draft the frame before Novo announces
You cannot price CagriSema today, and you should not try. What you can do is draft the frame against the anchors that already exist: Wegovy at roughly $199 a month through manufacturer channels, the Wegovy pill at $149, Zepbound vials at $299 to $449 by dose, and a maturing oral tier underneath. Three scenarios cover the space:
Premium launch. List price lands well above current injectables. Your move: position CagriSema as an escalation option inside the program, keep current molecules as the default start, and let provider judgment, not marketing, drive who steps up.
Parity launch. Pricing lands near Wegovy and Zepbound. Your move: present it as choice, not upgrade, and make your comparison content the cleanest in the category, because parity pricing turns selection into a pure clinical-fit question.
Access-aggressive launch. Novo uses price or direct channels to drive share. Your move: the floor-aware playbook you already run, where the program's value is wraparound care rather than access, priced transparently against manufacturer channels.
One scenario page per case, drafted now, means repricing week is an edit, not a debate. Keep the drafts internal; publish only the frame, the way the new products map handles watchlist items.
The day-one kit and the switch conversation
Two assets close out readiness. First, the prewritten decision-day post: what was approved, for whom, what the label says, what it means for patients on current medications, what your program will do and when. Write 80% of it now with blanks for the label specifics, and publish within hours of the news, because fast, dated coverage of a decision wins assistant citations for months. This is the same muscle as the 503B day-one playbook; build it once, run it for every catalyst.
Second, the answer for current patients who ask to switch, which they will, the day of the headline. The honest script: approval does not equal availability, availability does not equal fit, and switching a working regimen has real clinical tradeoffs. Tell them your team is evaluating it for the formulary, that their provider will discuss it at their next review if it becomes a fit, and that nobody stable on effective treatment should churn their regimen for a press release. Conservative answers age well: the trust they build outlasts any launch cycle.
FAQ
When will CagriSema be approved? Novo Nordisk has said a US decision is expected in Q4 2026, following the NDA filed December 18, 2025. There is no public PDUFA date, so programs should prepare for a decision that arrives without advance notice rather than trying to time it.
What is CagriSema and how effective is it? CagriSema is a once-weekly combination of semaglutide and the amylin analogue cagrilintide. The placebo-controlled REDEFINE-1 and REDEFINE-2 trials anchor its FDA filing; the REDEFINE-4 head-to-head showed 23% weight loss at 84 weeks but missed its non-inferiority endpoint against tirzepatide 15 mg.
Should telehealth programs offer CagriSema now? No. It is not FDA approved, so it belongs in watchlist education only: clearly not available, accurately described, with a visible update date. Programs should spend the pre-approval window on readiness, formulary and intake logic that can add a molecule as configuration, pricing scenarios, and a prewritten day-one post.
What happened to retatrutide's timeline? Reported plans now point to a filing around year-end 2026 or early 2027, with approval a 2027 to 2028 story. That is later than earlier signals suggested, which leaves CagriSema as the near-term catalyst worth building against, with retatrutide readiness reusing the same machinery next year.